PUBLISHER: Grand View Research | PRODUCT CODE: 2067543
PUBLISHER: Grand View Research | PRODUCT CODE: 2067543
The U.S. endobronchial ultrasound biopsy market size was estimated at USD 32.5 million in 2025 and is projected to reach USD 45.7 million by 2033, growing at a CAGR of 4.4% from 2026 to 2033. The market is also categorized into a procedure side which was estimated at USD 861.0 million in 2025 and is projected to grow at a CAGR of 6.5% from 2026 to 2033.
Key factors contributing to the market growth include rising incidence of lung cancer and respiratory disorders, rapid technological evolution and increasing market competition in the U.S. endobronchial ultrasound biopsy (EBUS) market. In addition, expansion of lung cancer screening programs, shift toward advanced bronchoscopy modalities driving EBUS adoption, favorable reimbursement and clinical guidelines.
The expansion of lung cancer screening programs across U.S. states is a key driver of EBUS adoption, as the increasing use of low-dose CT (LDCT) is leading to higher detection of early-stage lung nodules and mediastinal abnormalities that require confirmatory diagnosis and staging. State-led and community-based initiatives focused on improving access, reducing disparities, and integrating advanced technologies such as AI are expanding screening coverage among high-risk and underserved populations. This is significantly increasing patient volumes entering diagnostic pathways, thereby driving demand for minimally invasive procedures such as EBUS. For instance:
Moreover, the growing adoption of advanced bronchoscopy modalities, including electromagnetic navigation bronchoscopy and Ion-based robotic-assisted bronchoscopy, across U.S. hospitals is directly driving the transition away from conventional diagnostic approaches such as transthoracic needle aspiration (TTNA), traditional bronchoscopy, and surgical biopsy.
These technologies enable precise navigation to small, peripheral, and hard-to-reach lung nodules using 3D imaging, navigation systems, and robotic control, significantly improving diagnostic yield while reducing complications and invasiveness. As these modalities become integral to lung nodule evaluation, they are increasingly used in combination with EBUS for comprehensive diagnosis and staging, thereby directly contributing to higher EBUS procedural volumes.
For instance, in March 2026, Mercy Hospital Fort Smith introduced robotic-assisted bronchoscopy technology to enable more precise, minimally invasive diagnosis of lung nodules and improve early detection of lung disease. The system uses advanced 3D CT mapping and robotic navigation to access small or hard-to-reach lesions, allowing same-procedure biopsy while reducing the need for invasive surgeries and hospital stays.
U.S. Endobronchial Ultrasound Biopsy Market Report Segmentation
This report forecasts revenue growth at U.S. levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Endobronchial Ultrasound Biopsy market report based on the product side market (Equipment and Consumables), the procedure side market (Procedures, modality, CPT codes, end use).